Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using a Simplified Tool to Predict Lung Cancer Screening (LCS) Eligibility: Experiment to Test Effects of Messaging on Response Rates

NCT06133816 is registered in ClinicalTrials.gov with Abramson Cancer Center at Penn Medicine as lead sponsor.

NCT NCT06133816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06133816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using a Simplified Tool to Predict Lung Cancer Screening (LCS) Eligibility: Experiment to Test Effects of Messaging on Response Rates
Lead sponsor
Abramson Cancer Center at Penn Medicine
Phase
Not applicable
Overall status
Completed
Start date
July 31, 2023
Completion date
January 31, 2024
Enrollment
6,125 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer